Max Nisen, Columnist

Wait, Did Valeant Do Something Right?

An FDA panel OK of a new psoriasis drug comes with a raft of caveats.

July 20, 2016 at 4:29 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Here's a sentence to excavate from the vaults and give a good dusting: Valeant might have done something right.

A panel of FDA experts on Tuesday voted unanimously that Valeant's plaque psoriasis drug, brodalumab, deserved approval. The troubled pharmaceutical firm's shares rose more than 4 percent Wednesday morning as Valeant investor Bill Ackman talked it up on a call with investors. (The company also had a drug for opioid-induced constipation approved on Tuesday)